Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators

Daniel T. Monaghan, Mark W. Irvine, Blaise Mathias Costa, Guangyu Fang, David E. Jane

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The NMDA receptor (NMDAR) family of l-glutamate receptors are well known to have diverse roles in CNS function as well as in various neuropathological and psychiatric conditions. Until recently, the types of agents available to pharmacologically regulate NMDAR function have been quite limited in terms of mechanism of action and subtype selectivity. This has changed significantly in the past two years. The purpose of this review is to summarize the many drug classes now available for modulating NMDAR activity. Previously, this included competitive antagonists at the l-glutamate and glycine binding sites, high and low affinity channel blockers, and GluN2B-selective N-terminal domain binding site antagonists. More recently, we and others have identified new classes of NMDAR agents that are either positive or negative allosteric modulators (PAMs and NAMs, respectively). These compounds include the pan potentiator UBP646, the GluN2A-selective potentiator/GluN2C and GluN2D inhibitor UBP512, the GluN2D-selective potentiator UBP551, the GluN2C/GluN2D-selective potentiator CIQ as well as the new NMDAR-NAMs such as the pan-inhibitor UBP618, the GluN2C/GluN2D-selective inhibitor QZN46 and the GluN2A inhibitors UBP608 and TCN201. These new agents do not bind within the l-glutamate or glycine binding sites, the ion channel pore or the N-terminal regulatory domain. Collectively, these new allosteric modulators appear to be acting at multiple novel sites on the NMDAR complex. Importantly, these agents display improved subtype-selectivity and as NMDAR PAMs and NAMs, they represent a new generation of potential NMDAR therapeutics.

Original languageEnglish (US)
Pages (from-to)581-592
Number of pages12
JournalNeurochemistry International
Volume61
Issue number4
DOIs
StatePublished - Sep 1 2012

Fingerprint

N-Methyl-D-Aspartate Receptors
Pharmacology
Binding Sites
Glycine
Glutamic Acid
Glutamate Receptors
Ion Channels
Psychiatry
Pharmaceutical Preparations

Keywords

  • Allosteric modulators
  • Antagonists
  • Channel blockers
  • Competitive inhibitors
  • Glycine
  • NMDA receptors
  • Potentiators

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. / Monaghan, Daniel T.; Irvine, Mark W.; Costa, Blaise Mathias; Fang, Guangyu; Jane, David E.

In: Neurochemistry International, Vol. 61, No. 4, 01.09.2012, p. 581-592.

Research output: Contribution to journalArticle

Monaghan, Daniel T. ; Irvine, Mark W. ; Costa, Blaise Mathias ; Fang, Guangyu ; Jane, David E. / Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. In: Neurochemistry International. 2012 ; Vol. 61, No. 4. pp. 581-592.
@article{981eae6952104769bcdc2f9fa6243836,
title = "Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators",
abstract = "The NMDA receptor (NMDAR) family of l-glutamate receptors are well known to have diverse roles in CNS function as well as in various neuropathological and psychiatric conditions. Until recently, the types of agents available to pharmacologically regulate NMDAR function have been quite limited in terms of mechanism of action and subtype selectivity. This has changed significantly in the past two years. The purpose of this review is to summarize the many drug classes now available for modulating NMDAR activity. Previously, this included competitive antagonists at the l-glutamate and glycine binding sites, high and low affinity channel blockers, and GluN2B-selective N-terminal domain binding site antagonists. More recently, we and others have identified new classes of NMDAR agents that are either positive or negative allosteric modulators (PAMs and NAMs, respectively). These compounds include the pan potentiator UBP646, the GluN2A-selective potentiator/GluN2C and GluN2D inhibitor UBP512, the GluN2D-selective potentiator UBP551, the GluN2C/GluN2D-selective potentiator CIQ as well as the new NMDAR-NAMs such as the pan-inhibitor UBP618, the GluN2C/GluN2D-selective inhibitor QZN46 and the GluN2A inhibitors UBP608 and TCN201. These new agents do not bind within the l-glutamate or glycine binding sites, the ion channel pore or the N-terminal regulatory domain. Collectively, these new allosteric modulators appear to be acting at multiple novel sites on the NMDAR complex. Importantly, these agents display improved subtype-selectivity and as NMDAR PAMs and NAMs, they represent a new generation of potential NMDAR therapeutics.",
keywords = "Allosteric modulators, Antagonists, Channel blockers, Competitive inhibitors, Glycine, NMDA receptors, Potentiators",
author = "Monaghan, {Daniel T.} and Irvine, {Mark W.} and Costa, {Blaise Mathias} and Guangyu Fang and Jane, {David E.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.neuint.2012.01.004",
language = "English (US)",
volume = "61",
pages = "581--592",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators

AU - Monaghan, Daniel T.

AU - Irvine, Mark W.

AU - Costa, Blaise Mathias

AU - Fang, Guangyu

AU - Jane, David E.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The NMDA receptor (NMDAR) family of l-glutamate receptors are well known to have diverse roles in CNS function as well as in various neuropathological and psychiatric conditions. Until recently, the types of agents available to pharmacologically regulate NMDAR function have been quite limited in terms of mechanism of action and subtype selectivity. This has changed significantly in the past two years. The purpose of this review is to summarize the many drug classes now available for modulating NMDAR activity. Previously, this included competitive antagonists at the l-glutamate and glycine binding sites, high and low affinity channel blockers, and GluN2B-selective N-terminal domain binding site antagonists. More recently, we and others have identified new classes of NMDAR agents that are either positive or negative allosteric modulators (PAMs and NAMs, respectively). These compounds include the pan potentiator UBP646, the GluN2A-selective potentiator/GluN2C and GluN2D inhibitor UBP512, the GluN2D-selective potentiator UBP551, the GluN2C/GluN2D-selective potentiator CIQ as well as the new NMDAR-NAMs such as the pan-inhibitor UBP618, the GluN2C/GluN2D-selective inhibitor QZN46 and the GluN2A inhibitors UBP608 and TCN201. These new agents do not bind within the l-glutamate or glycine binding sites, the ion channel pore or the N-terminal regulatory domain. Collectively, these new allosteric modulators appear to be acting at multiple novel sites on the NMDAR complex. Importantly, these agents display improved subtype-selectivity and as NMDAR PAMs and NAMs, they represent a new generation of potential NMDAR therapeutics.

AB - The NMDA receptor (NMDAR) family of l-glutamate receptors are well known to have diverse roles in CNS function as well as in various neuropathological and psychiatric conditions. Until recently, the types of agents available to pharmacologically regulate NMDAR function have been quite limited in terms of mechanism of action and subtype selectivity. This has changed significantly in the past two years. The purpose of this review is to summarize the many drug classes now available for modulating NMDAR activity. Previously, this included competitive antagonists at the l-glutamate and glycine binding sites, high and low affinity channel blockers, and GluN2B-selective N-terminal domain binding site antagonists. More recently, we and others have identified new classes of NMDAR agents that are either positive or negative allosteric modulators (PAMs and NAMs, respectively). These compounds include the pan potentiator UBP646, the GluN2A-selective potentiator/GluN2C and GluN2D inhibitor UBP512, the GluN2D-selective potentiator UBP551, the GluN2C/GluN2D-selective potentiator CIQ as well as the new NMDAR-NAMs such as the pan-inhibitor UBP618, the GluN2C/GluN2D-selective inhibitor QZN46 and the GluN2A inhibitors UBP608 and TCN201. These new agents do not bind within the l-glutamate or glycine binding sites, the ion channel pore or the N-terminal regulatory domain. Collectively, these new allosteric modulators appear to be acting at multiple novel sites on the NMDAR complex. Importantly, these agents display improved subtype-selectivity and as NMDAR PAMs and NAMs, they represent a new generation of potential NMDAR therapeutics.

KW - Allosteric modulators

KW - Antagonists

KW - Channel blockers

KW - Competitive inhibitors

KW - Glycine

KW - NMDA receptors

KW - Potentiators

UR - http://www.scopus.com/inward/record.url?scp=84865746076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865746076&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2012.01.004

DO - 10.1016/j.neuint.2012.01.004

M3 - Article

C2 - 22269804

AN - SCOPUS:84865746076

VL - 61

SP - 581

EP - 592

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 4

ER -